CG Oncology Q1 net loss widens to $60.2M; BLA submission on track for Q4 2026

CG Oncology, Inc.

2026-Q1 EPS reported -$0.71 revenue$1,083,000

Net loss of $60.2M ($0.71 per share) vs $34.5M ($0.45) in Q1 2025.
Cash, cash equivalents & marketable securities $1.1B as of March 31, 2026; includes $391.4M from ATM sales.
BLA for cretostimogene in HR BCG-unresponsive NMIBC expected to complete in Q4 2026 after FDA alignment.
Phase 3 PIVOT-006 topline data in intermediate-risk NMIBC anticipated 1H 2026.
Appointed Jim DeTore as CFO in April 2026; he brings 30+ years life sciences experience.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-213440
form_type: 8-K
ticker: CGON
cik: 0001991792
company_name: CG Oncology, Inc.
filed_at: 2026-05-08T23:59:59+00:00
discovered_at: 2026-05-14T18:02:33.356917+00:00
generated_at: 2026-05-14T21:13:11.327967+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: neutral
materiality_score: 0.7
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-213440
json_url: https://secwatch.observer/filing/0001193125-26-213440.json
markdown_url: https://secwatch.observer/filing/0001193125-26-213440.md
text_url: https://secwatch.observer/filing/0001193125-26-213440.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1991792/000119312526213440/0001193125-26-213440-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1991792/000119312526213440/ck0001991792-20260508.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-26-213440

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.